Comparative Pharmacology
Head-to-head clinical analysis: NORLUTATE versus PROGESTERONE VAGINAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORLUTATE versus PROGESTERONE VAGINAL.
NORLUTATE vs Progesterone (Vaginal)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial transformation.
Progesterone binds to progesterone receptors in the reproductive tract, converting proliferative endometrium to secretory endometrium, and reduces gonadotropin secretion, inhibiting ovulation.
5 mg orally once daily for 5 days, starting on day 1 of menstrual cycle; for menorrhagia, 5 mg orally three times daily from day 19 to day 26 of cycle.
For progesterone deficiency (e.g., assisted reproductive technology, luteal phase support): 90 mg intravaginally once daily. For secondary amenorrhea: 45 mg intravaginally every other day for up to 12 doses, then 90 mg if needed. For threatened abortion: 200-400 mg intravaginally once or twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 5-6 hours. Clinical context: supports twice-daily dosing; steady state reached within 2 days.
The terminal elimination half-life of progesterone administered vaginally is approximately 5.5 to 6 hours (range: 4.5–8.0 hours) in women with normal renal and hepatic function. This short half-life necessitates twice-daily dosing for sustained effects.
Primarily renal (approximately 60% of metabolites, mostly glucuronides), with about 40% fecal/biliary elimination. Less than 1% excreted unchanged.
Primarily hepatic metabolism; about 50-60% of metabolites are excreted renally as glucuronide conjugates, with approximately 30-40% eliminated via feces. Less than 1% of unchanged progesterone is excreted in urine.
Category C
Category A/B
Progestin
Progestin